» Articles » PMID: 15527691

Hypertension and Liver Disease

Overview
Date 2004 Nov 6
PMID 15527691
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Arterial hypertension is a common disorder with a frequency of 10% to 15% in subjects in the 40- to 60-year age group. Yet most reports find the prevalence of arterial hypertension in patients with chronic liver disease (cirrhosis) much lower. In this review, we consider the alterations in systemic hemodynamics in cirrhosis. The most characteristic findings in cirrhotic patients are vasodilatation with low systemic vascular resistance, increased cardiac output, high arterial compliance, secondary activation of counterregulatory systems (sympathetic nervous system, renin-angiotensin-aldosterone system, neuropituitary release of vasopressin), and resistance to vasopressors. The vasodilatory state is mediated through nitric oxide, calcitonin gene-related peptide, adrenomedullin, and other vasodilators, and is most pronounced in the splanchnic area. This constitutes an effective (although relative) counterbalance to increased arterial blood pressure. Subjects with established arterial hypertension (essential, secondary) may become normotensive during the development of cirrhosis, and arterial hypertension is rarely manifested in patients with cirrhosis, even in cases with renovascular disease and high circulating renin activity. There is much dispute as to the understanding of homeostatic regulation in cirrhotic patients with manifest arterial hypertension. This is a topic for future research.

Citing Articles

REAC Reparative Treatment: A Promising Therapeutic Option for Alcoholic Cirrhosis of the Liver.

Pereira L, Pereira J, Fontani V, Rinaldi S J Pers Med. 2023; 13(12).

PMID: 38138925 PMC: 10744513. DOI: 10.3390/jpm13121698.


NGF (-198C > T, Ala35Val) and p75 (Ser205Leu) gene mutations are associated with liver function in different histopathological profiles of the patients with chronic viral hepatitis in the Brazilian Amazon.

Pereira L, da Silva Graca Amoras E, Conde S, Demachki S, Dos Santos E, Lima S Mol Med. 2020; 26(1):12.

PMID: 31996124 PMC: 6990582. DOI: 10.1186/s10020-019-0134-x.


Coronary artery disease in patients with liver cirrhosis.

Kalaitzakis E, Rosengren A, Skommevik T, Bjornsson E Dig Dis Sci. 2009; 55(2):467-75.

PMID: 19242795 DOI: 10.1007/s10620-009-0738-z.


Arthur C. Corcoran Memorial Lecture. Sympathetic activity, vascular capacitance, and long-term regulation of arterial pressure.

Fink G Hypertension. 2008; 53(2):307-12.

PMID: 19114645 PMC: 2685147. DOI: 10.1161/HYPERTENSIONAHA.108.119990.


Altered central TRPV4 expression and lipid raft association related to inappropriate vasopressin secretion in cirrhotic rats.

Carreno F, Ji L, Cunningham J Am J Physiol Regul Integr Comp Physiol. 2008; 296(2):R454-66.

PMID: 19091909 PMC: 2643982. DOI: 10.1152/ajpregu.90460.2008.


References
1.
Gines P, Guevara M, Arroyo V, Rodes J . Hepatorenal syndrome. Lancet. 2003; 362(9398):1819-27. DOI: 10.1016/S0140-6736(03)14903-3. View

2.
LOYKE H, CUTARELLI R . An evaluation of hypertension and liver disease in an alcoholic service. Am J Med Sci. 1960; 240:346-8. DOI: 10.1097/00000441-196009000-00011. View

3.
Moller S, Gulberg V, Henriksen J, Gerbes A . Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol. 1995; 23(2):135-44. DOI: 10.1016/0168-8278(95)80327-0. View

4.
Moller S, Henriksen J, Bendtsen F . Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol. 2003; 284(6):G970-9. DOI: 10.1152/ajpgi.00521.2002. View

5.
LOYKE H . Reduction of hypertension after liver disease. Arch Intern Med. 1962; 110:45-9. DOI: 10.1001/archinte.1962.03620190047006. View